Bioactive Compounds (RA2 Sample Clauses

Bioactive Compounds (RA2. 4) This sub-platform network will be led by DFVF with support form IFR and UCC. Their individual responsibilities are shown below under planned activities and key deliverables. The overall objective of this platform is to implement the EU BASIS database on critically assessed and validated data on health protective constituents in more than 300 European food plants to the EuroFIR databank environment. The specific objectives are as follows: • To establish and populate a web-based database on critically assessed composition data on bioactive constituents in plant and non-plant-based foods (including wine, chocolate & soya products). • To extend the web-based database system to allow the inclusion of critically assessed biological effects data on bioactive constituents. • To update the plant and plant part lists to include major European food plants in 15 European languages, and to produce new lists covering exotic food plants, health food plants, and processed plant based foods. • To deploy the database in an internet environment to facilitate accessibility for stakeholders and end-users including food authorities, researchers, industry and consumers for general diet and health considerations and in order to support the evaluation of genetically modified foods e.g. plant foods. • To ensure compatibility of the EuroFIR-BASIS database with the standard specifications developed for the EuroFIR databank system. There is a need for an information system containing critically assessed data on the biological activities of bioactive components (e.g. glucosinolates, isoflavones, lignans, polyphenols and carotenoids) with putative health benefit, present in a form in which it can be made available for health authorities, scientists in food industry and academia, and consumers. The database will serve as a tool to provide basic compositional and biological information on other bioactive food plant constituents, including putative health-protective factors in: • The evaluation of genetically modified food plants; • The evaluation of other new food plants and varieties; • The general evaluation of diet and health considerations of food plants. It is also an important issue to extend and update the information in the existing BASIS database. The food plants will be selected on the basis of their content of bioactive constituents and their perceived beneficial and possible risk effects, as well as on an assessment of the commercial importance of the crop and its place in ...
Sample 1
AutoNDA by SimpleDocs
Bioactive Compounds (RA2. 4) This sub-platform network will be led by DFVF with support form IFR and UCC. Their individual responsibilities are shown below under planned activities and key deliverables. The overall objective of this WP is to implement the EU BASIS database on critically assessed and validated data on health protective constituents in more than 300 European food plants to the EuroFIR databank environment. There is a need for an information system containing critically assessed data on the biological activities of bioactive components (e.g. glucosinolates, isoflavones, lignans, polyphenols and carotenoids) with putative health benefit, present in a form in which it can be made available for health authorities, scientists in food industry and academia, and consumers. The database will serve as a tool to provide basic compositional and biological information on other bioactive food plant constituents, including putative health-protective factors in: • The evaluation of genetically modified food plants; • The evaluation of other new food plants and varieties; • The general evaluation of diet and health considerations of food plants. It is also an important issue to extend and update the information in the existing BASIS database. The food plants will be selected on the basis of their content of bioactive constituents and their perceived beneficial and possible risk effects, as well as on an assessment of the commercial importance of the crop and its place in the human diet. The specific tasks of this WP will be:
Sample 1

Related to Bioactive Compounds (RA2

  • Biological Samples If so specified in the Protocol, Institution and Principal Investigator may collect and provide to Sponsor or its designee Biological Samples (“Biological Samples”). 12.2.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Hepatitis B Vaccine Where the Hospital identifies high risk areas where employees are exposed to Hepatitis B, the Hospital will provide, at no cost to the employees, a Hepatitis B vaccine.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • SHOP DRAWINGS, PRODUCT DATA AND SAMPLES 4.12.1 Shop Drawings are drawings, diagrams, schedules and other, data specially prepared for the Work by the Contractor or any Subcontractor, manufacturer, supplier or distributor to illustrate some portion of the Work.

  • Geographical Indications 1. Each Party shall recognise that geographical indications may be protected through a trade xxxx or sui generis system or other legal means in accordance with its laws and regulations.

  • Licensed Products Lessee will obtain no title to Licensed Products which will at all times remain the property of the owner of the Licensed Products. A license from the owner may be required and it is Lessee's responsibility to obtain any required license before the use of the Licensed Products. Lessee agrees to treat the Licensed Products as confidential information of the owner, to observe all copyright restrictions, and not to reproduce or sell the Licensed Products.

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!